LDLR and colonic neoplasm: Moreover, despite the theoretical postulation that elevated bile acid levels493—induced by more cholesterol uptake by the liver due to the upregulation of LDLR by PCSK9 antibodies—could stimulate bile acid production, leading to colon tumors in rodents, no anomalies were discerned in either rodent or non-rodent toxicity studies during the clinical review of Alirocumab and Evolocumab by the US FDA.